Literature DB >> 10898794

Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.

K Inoue1, R Wen, J E Rehg, M Adachi, J L Cleveland, M F Roussel, C J Sherr.   

Abstract

The DMP1 transcription factor induces the ARF tumor suppressor gene in mouse fibroblasts, leading to cell cycle arrest in a p53-dependent manner. We disrupted sequences encoding the DNA-binding domain of DMP1 in mouse embryonic stem cells and derived animals lacking the functional protein. DMP1-null animals are small at birth, and males develop more slowly than their wild-type littermates. Some adult animals exhibit seizures and/or obstuctive uropathy, each of unknown cause. The growth of explanted DMP1-null mouse embryo fibroblasts (MEFs) is progressively retarded as cells are passaged in culture on defined transfer protocols; but, unlike the behavior of normal cells, p19(ARF), Mdm2, and p53 levels remain relatively low and DMP1-null MEFs do not senesce. Whereas the establishment of cell lines from MEFs is usually always accompanied by either p53 or ARF loss of function, continuously passaged DMP1-null cells readily give rise to established 3T3 and 3T9 cell lines that retain wild-type ARF and functional p53 genes. Early-passage DMP1-null cells, like MEFs from either ARF-null or p53-null mice, can be morphologically transformed by oncogenic Ha-Ras (Val-12) alone. Splenic lymphocytes harvested from both DMP1-null and ARF-null mice exhibit enhanced proliferative responses in long-term cultures when stimulated to divide with antibody to CD3 and interleukin-2. Although only 1 of 40 DMP1-null animals spontaneously developed a tumor in the first year of life, neonatal treatment with dimethylbenzanthracene or ionizing radiation induced tumors of various histologic types that were not observed in similarly treated DMP1(+/+) animals. Karyotypic analyses of MEFs and lymphomas from DMP1-null animals revealed pseudodiploid chromosome numbers, consistent with the retention of wild-type p53. Together, these data suggest that ARF function is compromised, but not eliminated, in animals lacking functional DMP1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898794      PMCID: PMC316790     

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  68 in total

1.  Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.

Authors:  J W Harbour; R X Luo; A Dei Santi; A A Postigo; D C Dean
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

2.  Obstructive uropathy in laboratory mice.

Authors:  V I Babcock; C M Southam
Journal:  Proc Soc Exp Biol Med       Date:  1965-11

3.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

Authors:  W Tao; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.

Authors:  C Pantoja; M Serrano
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

5.  Twist is a potential oncogene that inhibits apoptosis.

Authors:  R Maestro; A P Dei Tos; Y Hamamori; S Krasnokutsky; V Sartorelli; L Kedes; C Doglioni; D H Beach; G J Hannon
Journal:  Genes Dev       Date:  1999-09-01       Impact factor: 11.361

6.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

7.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion.

Authors:  S H Khan; J Moritsugu; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines.

Authors:  G J TODARO; H GREEN
Journal:  J Cell Biol       Date:  1963-05       Impact factor: 10.539

View more
  52 in total

Review 1.  Comparative pathogenesis of epsilonretroviruses.

Authors:  Donald Holzschu; Lorie A Lapierre; Michael D Lairmore
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

3.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

4.  Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs.

Authors:  A Mallakin; P Taneja; L A Matise; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2006-07-31       Impact factor: 9.867

5.  A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.

Authors:  Alexander D Boiko; Sarah Porteous; Olga V Razorenova; Vadim I Krivokrysenko; Bryan R Williams; Andrei V Gudkov
Journal:  Genes Dev       Date:  2006-01-15       Impact factor: 11.361

6.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

7.  Aberrant expression of p16INK4a in human cancers - a new biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Rep Rev       Date:  2018-01-15

Review 8.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

9.  G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.

Authors:  Gilles Doumont; Alain Martoriati; Chantal Beekman; Sven Bogaerts; Patrick J Mee; Fabrice Bureau; Emanuela Colombo; Myriam Alcalay; Eric Bellefroid; Francesco Marchesi; Eugenio Scanziani; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

10.  Arf tumor suppressor promoter monitors latent oncogenic signals in vivo.

Authors:  Frederique Zindy; Richard T Williams; Troy A Baudino; Jerold E Rehg; Stephen X Skapek; John L Cleveland; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.